What is PROMETRIKA?
PROMETRIKA operates as a full-service Clinical Research Organization (CRO), providing end-to-end support for product development cycles ranging from pre-IND stages through to Phase 4 clinical trials. The company distinguishes itself through deep expertise in regulatory affairs and clinical operations, particularly within high-stakes therapeutic domains such as oncology and rare disease research. With a legacy spanning over two decades, the firm has successfully navigated the rigorous requirements of both the FDA and EMA, establishing a reputation for precision in regulatory submissions and trial execution. Their market position is defined by a commitment to quality, serving a diverse portfolio of international clients who require specialized guidance in bringing complex medical therapies to market.
How much funding has PROMETRIKA raised?
PROMETRIKA has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in PROMETRIKA
PPP
Public-Private Partnership
What's next for PROMETRIKA?
With the recent capital injection, PROMETRIKA is well-positioned to accelerate its strategic growth initiatives. The firm is expected to enhance its technological capabilities in data management and regulatory compliance, further streamlining the path to market for its partners. As the demand for specialized CRO services in rare disease research continues to climb, PROMETRIKA will likely focus on expanding its global footprint and deepening its therapeutic expertise. This phase of development marks a transition toward more integrated, data-driven clinical solutions, ensuring the company remains a critical partner for innovators navigating the increasingly complex global regulatory environment.
See full PROMETRIKA company page
